Cristina M. Rondinone


President and Member of the Board of Directors

Dr. Cristina Rondinone was appointed President of Cellarity and member of the Board of Directors in September of 2019. She brings to the company more than 20 years of experience in the biopharmaceutical industry with a record of successfully leading the discovery and development of numerous molecules. She joins Cellarity from MedImmune-AstraZeneca, where she was Senior Vice President and Head of Cardiovascular, Renal, and Metabolic Diseases. During her tenure, she created the therapeutic area and led cross-functional teams responsible for strategy, growth, and advancement of the portfolio, including research, translational medicine, and development. She led the way to advance a number of programs from research to Phase 2b trials in record time. In addition, she was an active member of the company leadership team. Prior to MedImmune, Dr. Rondinone held leadership positions at Hoffmann-La Roche and Abbott Laboratories.

Before joining the pharmaceutical industry, she was Associate Professor (Docent) of Molecular Medicine at the University of Gothenburg in Sweden. Dr. Rondinone received her Ph.D. in Biochemistry from the University of Buenos Aires. Her postdoctoral training was at the Laboratory of Cellular and Developmental Biology at NIDDK, National Institutes of Health, USA.

Dr. Rondinone has authored more than 80 peer-reviewed publications and currently holds 5 patents. She was also editor of the book, Therapeutic Applications of RNAi.

She has been a member of the Board of Directors of Axcella Health since June 2018. Additionally, she is a member of the Scientific Advisory Board for the Keystone Symposia and Axcella Health as well as a member of the Royal National Pharmaceutical Academy in Spain.


Group 49 Created with Sketch.